[
  {
    "symbol": "RVMD",
    "price": 26.76,
    "beta": 1.443588,
    "volAvg": 994079,
    "mktCap": 2844935880,
    "lastDiv": 0,
    "range": "17.005-31.37",
    "changes": 1.09,
    "companyName": "Revolution Medicines, Inc.",
    "currency": "USD",
    "cik": "0001628171",
    "isin": "US76155X1000",
    "cusip": "76155X100",
    "exchange": "NASDAQ Global Select",
    "exchangeShortName": "NASDAQ",
    "industry": "Biotechnology",
    "website": "https://www.revmed.com",
    "description": "Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.",
    "ceo": "Dr. Mark A. Goldsmith Ph.D.",
    "sector": "Healthcare",
    "country": "US",
    "fullTimeEmployees": "259",
    "phone": "650 481 6801",
    "address": "700 Saginaw Drive",
    "city": "Redwood City",
    "state": "CA",
    "zip": "94063",
    "dcfDiff": null,
    "dcf": 0,
    "image": "https://financialmodelingprep.com/image-stock/RVMD.png",
    "ipoDate": "2020-02-13",
    "defaultImage": false,
    "isEtf": false,
    "isActivelyTrading": true,
    "isAdr": false,
    "isFund": false
  }
]